Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.

被引：0
|
作者：
Garcia-Alfonso, Pilar
Munoz Martin, Andres J.
Jimenez-Castro, Jeronimo
Jimenez-Fonseca, Paula
Pericay, Carles
Longo, Federico
Reyna, Carmen
Argiles, Guillem
Gonzalez Astorga, Beatriz
Jose Gomez-Reina, Maria
Ruiz Casado, Ana
Rodriguez-Salas, Nuria
Lopez-Lopez, Rafael
Carmona Bayonas, Alberto
Conde-Herrero, Veronica
Aranda, Enrique
机构：
[1] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[2] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[3] Hosp Univ Virgen Rocio, Seville, Spain
[4] Hosp Univ Cent Asturias, Oviedo, Spain
[5] Hosp Sabadell, Corp Sanitaria Parc Tauli, Sabadell, Spain
[6] Inst Ramon & Cajal Invest Sanitaria IRICYS, Hosp Univ Ramon & Cajal, CIBERONC, Madrid, Spain
[7] Hosp Univ Reg & Virgen Victoria, Malaga, Spain
[8] Vall Hebron Univ Hosp & Inst Oncol VHIO, TTD Grp, CIBERONC, Barcelona, Spain
[9] Hosp Univ San Cecilio, Granada, Spain
[10] Hosp Univ Puerta Mar, Cadiz, Spain
[11] Hosp Univ Puerta Hierro, Dept Med Oncol, Madrid, Spain
[12] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[13] Univ Clin Hosp, Dept Med Oncol, Madrid, Spain
[14] Univ Clin Hosp, Translat Med Oncol Grp, Madrid, Spain
[15] Univ Clin Hosp, Hlth Res Inst IDIS, Madrid, Spain
[16] Univ Santiago Compostela, Sch Med, CIBERONC, Santiago De Compostela, Spain
[17] Hosp Gen Univ Morales Meseguer, Murcia, Spain
[18] Hosp Univ Virgen Ias Nieves, Dept Med Oncol, Granada, Spain
[19] Univ Cordoba, Reina Sofia Hosp, IMIBIC, Inst Salud Carlos III,CIBERONC, Cordoba, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e15556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15556
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    BMC CANCER, 2019, 19 (01)
  • [42] Effectiveness and safety of trifluridine/tipiracil in patients with metastatic colorectal cancer in clinical practice in Poland
    Radecka, B.
    Gelej, M.
    Streb, J.
    Siedlaczek, A.
    Kryka, K.
    Tokajuk, P.
    Winsko-Szczesnowicz, K.
    Czernek, U.
    Sobczak, M.
    Malik, M.
    Bodnar, L.
    Foszczynska-Kloda, M.
    Hetman, K.
    Skiewicz, M. Welnicka-Ja
    Wierzbicka, K.
    Orlikowska, M.
    Becht, R.
    Deptala, A.
    Itrych, B.
    Kania-Zembaczynska, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S108 - S108
  • [43] Real-world experience with trifluridine/tipiracil on metastatic colorectal cancer in a third level hospital
    Rosero Rodriguez, D.
    Perez de Aguado, P.
    Chamorro Perez, J.
    Albarran Fernandez, V.
    Longo, F.
    Reguera Puertas, P.
    Delfrade, M.
    Fuentes Mateos, R.
    Guillen-Ponce, C.
    Lopez Gomez, V.
    Rodriguez Garrote, M.
    Vaz, M.
    Villamayor Delgado, M.
    Fernandez Fradejas, J.
    Garrido, P.
    Gil, M.
    Pozas, J.
    Gemeno Lopez, E.
    Sotoca Rubio, P.
    Alia Navarro, V.
    Barrill Corpa, A.
    Ferreiro Monteagudo, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S84 - S84
  • [44] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Daisuke Kotani
    Yasutoshi Kuboki
    Satoshi Horasawa
    Asumi Kaneko
    Yoshiaki Nakamura
    Akihito Kawazoe
    Hideaki Bando
    Hiroya Taniguchi
    Kohei Shitara
    Takashi Kojima
    Akihito Tsuji
    Takayuki Yoshino
    BMC Cancer, 19
  • [45] Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis
    Prejac, Juraj
    Omcen, Tomislav
    Radic, Jasna
    Vrdoljak, Eduard
    Frobe, Ana
    Plestina, Stjepko
    ONCOLOGY, 2024, 102 (03) : 217 - 227
  • [46] A real-world comparison of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer in the United States
    Nevala-Plagemann, Christopher Duane
    Ying, Jian
    Sama, Shashank
    Florou, Vaia
    Haaland, Benjamin
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
    Ogata, Misato
    Kotaka, Masahito
    Ogata, Takatsugu
    Hatachi, Yukimasa
    Yasui, Hisateru
    Kato, Takeshi
    Tsuji, Akihito
    Satake, Hironaga
    PLOS ONE, 2020, 15 (06):
  • [48] A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States
    Nevala-Plagemann, Christopher
    Sama, Shashank
    Ying, Jian
    Shen, Jincheng
    Haaland, Benjamin
    Florou, Vaia
    Garrido-Laguna, Ignacio
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (03): : 257 - 264
  • [49] QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Ohtsu, Atsushi
    Amellal, Nadia
    Cadour, Stephanie
    Fougeray, Ronan
    Haffemayer, Benjamin
    Mayer, Robert J.
    ESMO OPEN, 2017, 2 (05)
  • [50] Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil
    Puthiamadathil, Jeevan M.
    Weinberg, Benjamin A.
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 461 - 469
12345